JP7115671B2 - 新規なｍｃｔ４阻害剤及びその使用 - Google Patents

新規なｍｃｔ４阻害剤及びその使用 Download PDF

Info

Publication number
JP7115671B2
JP7115671B2 JP2021509963A JP2021509963A JP7115671B2 JP 7115671 B2 JP7115671 B2 JP 7115671B2 JP 2021509963 A JP2021509963 A JP 2021509963A JP 2021509963 A JP2021509963 A JP 2021509963A JP 7115671 B2 JP7115671 B2 JP 7115671B2
Authority
JP
Japan
Prior art keywords
mct4
cancer
subject
pharmaceutical composition
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021509963A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522345A5 (OSRAM
JP2021522345A (ja
Inventor
ヨン ウー，
ジェイ ヴァドガマ，
チミン ファン，
ケー ウー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE
Original Assignee
CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE filed Critical CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE
Publication of JP2021522345A publication Critical patent/JP2021522345A/ja
Publication of JP2021522345A5 publication Critical patent/JP2021522345A5/ja
Application granted granted Critical
Publication of JP7115671B2 publication Critical patent/JP7115671B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/66—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021509963A 2018-04-25 2019-04-25 新規なｍｃｔ４阻害剤及びその使用 Active JP7115671B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662637P 2018-04-25 2018-04-25
US62/662,637 2018-04-25
PCT/US2019/029192 WO2020033019A2 (en) 2018-04-25 2019-04-25 Novel mct4 inhibitors and uses thereof

Publications (3)

Publication Number Publication Date
JP2021522345A JP2021522345A (ja) 2021-08-30
JP2021522345A5 JP2021522345A5 (OSRAM) 2022-04-28
JP7115671B2 true JP7115671B2 (ja) 2022-08-09

Family

ID=68532786

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021509963A Active JP7115671B2 (ja) 2018-04-25 2019-04-25 新規なｍｃｔ４阻害剤及びその使用

Country Status (7)

Country Link
US (1) US10919878B2 (OSRAM)
EP (1) EP3784650B1 (OSRAM)
JP (1) JP7115671B2 (OSRAM)
CN (1) CN112888673B (OSRAM)
AU (1) AU2019317518B2 (OSRAM)
CA (1) CA3098189C (OSRAM)
WO (1) WO2020033019A2 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12544375B2 (en) * 2019-09-05 2026-02-10 The Board Of Trustees Of The Leland Junior University Small molecule therapeutic for parkinson's disease paired with a biomarker of therapeutic activity
WO2021249969A1 (en) * 2020-06-10 2021-12-16 Merck Patent Gmbh Combination product for the treatment of cancer diseases
US20240270749A1 (en) 2021-05-21 2024-08-15 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 1,2,4-triazolo[1,5-a]pyrimidine-based slc16a3 inhibitors and their therapeutic use
WO2022243574A1 (en) 2021-05-21 2022-11-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 3-(phthalazin-1-yl)benzenesulfonamide-based slc16a3 inhibitors and their therapeutic use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017538689A (ja) 2014-11-17 2017-12-28 ニーロジョン セラピューティクス インコーポレイテッドＮｉｒｏｇｙｏｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． モノカルボン酸輸送修飾薬およびその使用
JP2018502874A (ja) 2015-01-22 2018-02-01 ザ スクリプス リサーチ インスティテュート プテリジンジオンモノカルボン酸トランスポータ阻害薬

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1226438A (OSRAM) 1968-12-03 1971-03-31
GB0327734D0 (en) * 2003-11-28 2003-12-31 Novartis Ag Organic compounds
TW200804349A (en) * 2005-12-23 2008-01-16 Kalypsys Inc Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases
WO2010089580A1 (en) * 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
CN102731413A (zh) * 2011-04-15 2012-10-17 上海医药工业研究院 一种脲类化合物、其制备方法、其中间体及其应用
WO2014189152A1 (en) 2013-05-24 2014-11-27 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
WO2016118822A1 (en) * 2015-01-22 2016-07-28 The Scripps Research Institute Chromenone inhibitors of monocarboxylate transporters
AU2016277126A1 (en) * 2015-06-12 2017-12-14 Vettore, LLC MCT4 inhibitors for treating disease
AU2017444054B2 (en) * 2017-12-21 2021-10-07 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Class of pyrimidine derivative kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017538689A (ja) 2014-11-17 2017-12-28 ニーロジョン セラピューティクス インコーポレイテッドＮｉｒｏｇｙｏｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． モノカルボン酸輸送修飾薬およびその使用
JP2018502874A (ja) 2015-01-22 2018-02-01 ザ スクリプス リサーチ インスティテュート プテリジンジオンモノカルボン酸トランスポータ阻害薬

Also Published As

Publication number Publication date
AU2019317518A1 (en) 2020-12-17
CA3098189A1 (en) 2020-02-13
AU2019317518B2 (en) 2023-05-25
EP3784650A4 (en) 2022-01-26
EP3784650B1 (en) 2023-09-06
WO2020033019A2 (en) 2020-02-13
CN112888673A (zh) 2021-06-01
CA3098189C (en) 2025-05-13
CN112888673B (zh) 2022-07-29
US20190352282A1 (en) 2019-11-21
WO2020033019A3 (en) 2020-04-02
US10919878B2 (en) 2021-02-16
EP3784650C0 (en) 2023-09-06
JP2021522345A (ja) 2021-08-30
EP3784650A2 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
Nagasawa et al. Temozolomide and other potential agents for the treatment of glioblastoma multiforme
JP6294889B2 (ja) ウイルス疾患の処置におけるｍｅｋ阻害物質
CN112888673B (zh) 新颖mct4抑制剂及其用途
US20130116208A1 (en) Administration of a nedd8-activating enzyme inhibitor and hypomethylating agent
WO2005082349A1 (en) Composition for the treatment of obesity comprising fumagillol derivative
US11446353B2 (en) Compositions and methods for the treatment of fungal infections
TR201806828T4 (tr) Gut ve hiperürisemi tedavisi.
US20150005252A1 (en) Combination therapy for the treatment of cancer
BR112020018601A2 (pt) Regime de dosagem de modulador de montagem de capsídeo
US20240197743A1 (en) Wee1 compound for treating uterine serous carcinoma
US20150306110A1 (en) Compositions and methods for treatment of inflammation and hyperkeratotic lesions
CN106692150B (zh) 尼达尼布在制备预防和治疗肝纤维化与肝硬化的药物中的用途
US20230381119A1 (en) Use of histone acetyltransferase inhibitor amidoximes as anti-proliferative agents
EP4247361B1 (en) Combination therapy for the treatment of a liver disease
EP3565547B1 (en) Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
US20060211672A1 (en) Use of estrogen receptor-beta selective agonists for radiation-or chemotherapy-induced mucositis and radiation cystitis
TW202308641A (zh) 用於治療癌症之方法及包含cdk抑制劑之給藥方案
WO2016201581A1 (en) Method of treating medulloblastoma
TWI899092B (zh) 用於神經退化性病症之治療之銅複合物
CN107412223A (zh) 一种含氧杂环化合物的医药用途
CA3286442A1 (en) Pharmaceutical composition and use thereof
HK40096221B (en) Combination therapy for the treatment of a liver disease
HK40096221A (en) Combination therapy for the treatment of a liver disease
Hua et al. A transdermal glucosamine formulation improves osteoarthritic symptoms in an open clinical survey
TW202539665A (zh) Fgfr4抑制劑與ppar促效劑之組合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220420

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220420

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220621

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220713

R150 Certificate of patent or registration of utility model

Ref document number: 7115671

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250